Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing ...

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Seal Rock Therapeutics joins The Michael J. Fox Foundation's LITE program to help advance research and developments in ...

Oikos Fusion offers a nutrient-dense dairy drink designed to support muscle mass and digestive health during weight loss ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...